Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (28)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zinzani, P. L.
Right arrow Articles by Tura, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zinzani, P. L.
Right arrow Articles by Tura, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 11:363-365, 2000
© 2000 European Society for Medical Oncology

other

Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas

P. L. Zinzani, M. Magagnoli, M. Bendandi, F. Gherlinzoni, G. Fraternali Orcioni, C. Cellini, V. Stefoni, S. A. Pileri and S. Tura

Institute of Hematology and Medical Oncology ‘Serdgnolt’, University of Bologna Italy

Correspondence to: P. L. Zinzani, MD, Istituto di Ematologia e Oncologia Medica ‘Seràgnoli’ Policlinico S. Orsola, Via Massarenti 9, 40138 Bologna, Italy. E-mail: plzmzo{at}med.unibo.it

Purpose: In the last years, fludarabine (FLU) alone or in combination with other drugs has been reported to be effective in the treatment of previously treated low-grade non-Hodgkin's lymphomas (LG-NHL). The aim of this study was to define the therapeutic efficacy and toxicity of a combination of FLU and mitoxantrone (FN regimen) in untreated LG-NHL.

Patients and methods: We used a two-drug combination of FLU (25 mg/m2 i.v. on days 1 to 3) and mitoxantrone (10 mg/m2 i.v. on day 1) to treat 27 previously untreated patients with LG-NHL. Chemotherapy was repeated every four weeks for a total of six cycles. Among 27 patients, 17 (63%) were diagnosed with follicular, 6 (22%) with small lymphocytic, and 4 (15%) with immunocytoma subtypes.

Results: Of the 27 patients, 18 (67%) achieved complete response (CR) and 6 (22%) partial response, while the remaining 3 (11%) showed no benefit from the treatment. Regarding histology, in the follicular subtype we observed an overall response rate of 94%, with a 76.5% CR rate. The estimated two-year relapse-free survival was 83%, and overall survival was 92%. Hematologic grade 3–4 toxicity was seen in only five (3.3%) patients; no opportunistic infections or deaths were associated with the administration of the FN regimen.

Conclusions: These preliminary data show that the FN regimen is a very active, well-tolerated combination chemotherapy for untreated patients with advanced LG-NHL.

first-line therapy, fludarabine and mitoxantrone, LG-NHL


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
P. L. Zinzani, A. Pulsoni, A. Perrotti, S. Soverini, F. Zaja, A. De Renzo, S. Storti, V. M. Lauta, L. Guardigni, P. Gentilini, et al.
Fludarabine Plus Mitoxantrone With and Without Rituximab Versus CHOP With and Without Rituximab As Front-Line Treatment for Patients With Follicular Lymphoma
J. Clin. Oncol., July 1, 2004; 22(13): 2654 - 2661.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. S. Velasquez, D. Lew, T. M. Grogan, C. H. Spiridonidis, S. P. Balcerzak, S. R. Dakhil, T. P. Miller, K. S. Lanier, R. A. Chapman, and R. I. Fisher
Combination of Fludarabine and Mitoxantrone in Untreated Stages III and IV Low-Grade Lymphoma: S9501
J. Clin. Oncol., May 15, 2003; 21(10): 1996 - 2003.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.